Helleva (lodenafil carbonate 80 mg) is a new PDE5 inhibitor (like Viagra, Cialis and Levitra) that was developed and gained regulatory approval in Brazil by Cristalia Pharmaceuticals. Recent studies have shown Lodenafil carbonate was more potent to inhibit the cGMP hydrolysis in PDE extracts compared with sildenafil (Viagra) .Cristalia has recently undergone phase 3 trials of Helleva with positive results. Click here to see report.
Lodenafil is formulated as a dimer, lodenafil carbonate, which breaks down in the body to form two molecules of the active drug lodenafil. This formulation provides a greater oral bioavailability than the parent drug and so increased effectiveness may be achieved by a greater number of patients. |
